Company: BGLC
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001477932-25-008343
Chunk: 35

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 35
---
,376   -   42,376 Others  3,549   36,865   -   40,414 TOTAL OTHER INCOME  22,101   85,659   -   107,760                  OPERATING EXPENSES                Sales and marketing  (30,211)  (508,683)  (12,675)  (551,569)Research and development  (14,876)  -   -   (14,876)General and administrative  (55,835)  (205,740)  (184,116)  (445,691)Provision for expected credit losses   -   (175,818)  -   (175,818)TOTAL OPERATING EXPENSES  (100,922)  (890,241)  (196,791)  (1,187,954)                 LOSS FROM OPERATIONS  (74,917)  (430,801)  (196,791)  (702,509)                 FINANCE COSTS  (3,115)  (3,165)  (202)  (6,482)                 NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS  $(78,032) $(433,966) $(196,993) $(708,991)

 27Table of Contents

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024 

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

  Provision for genomic screening services  Trading of industrial chemicals  Investment holding  Total   Nine months period ended September 30, 2024              REVENUE $11,224  $6,975,567  $-  $6,986,791                  COST OF REVENUE  (6,723)  (5,999,781)  -   (6,006,504)                 GROSS PROFIT  4,501